The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia
Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respective...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2017-05, Vol.17 (5), p.320-325 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 325 |
|---|---|
| container_issue | 5 |
| container_start_page | 320 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 17 |
| creator | Alabdulwahab, Amal S Elsayed, Hussein G Sherisher, Mohamed A Elbjeirami, Wafa M Alieldin, Nelly |
| description | Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis. |
| doi_str_mv | 10.1016/j.clml.2017.02.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881447059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2152265016305560</els_id><sourcerecordid>1881447059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-98a954f9cf3d6c7f2be672f1703c962f59d7cd8d878644fa504cd0ff0c35b1963</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIREvhBVggL9lksD3_CCGNQguVIoGUIMTK8tjXjVOPnfoHkTfiMXFI6YIFK9vX5xzp3u8WxUuCS4JJ-2ZXCjObkmLSlZiWGPePinNKGrqgbTs8frg3-Kx4FsIO4w5jMjwtzmhf1dWAm_Pi12YL6AO3HF1xP4FHS2eD81GnGX3xLjrhDFLOo5h1Gw88zmAjcgqN0hkIIr8C4lai7y7Zm1xNJhe-6bhFo0gR0Oow77duMjxELdAK0i3Mmr9FI1pre2MAXdv8E1PUzqLLn3vwGqwApC1a8yQ1Gj2fNH9ePFHcBHhxf14UX68uN8tPi9Xnj9fLcbUQNSFxMfR8aGo1CFXJVnSKTtB2VJEOV2JoqWoG2QnZy77r27pWvMG1kFgpLKpmIkNbXRSvT7l77-4ShMhmnbs0hltwKTDS96SuO9wMWUpPUuFdCB4U23s9c39gBLMjIbZjR0LsSIhhyjKhbHp1n5-mGeSD5S-SLHh3EkDu8ocGz4L4MxGpPYjIpNP_z3__j10YbbXg5hYOEHYueZvnxwgL2cDWxx05rghpK9w0La5-A2TGuQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1881447059</pqid></control><display><type>article</type><title>The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Alabdulwahab, Amal S ; Elsayed, Hussein G ; Sherisher, Mohamed A ; Elbjeirami, Wafa M ; Alieldin, Nelly</creator><creatorcontrib>Alabdulwahab, Amal S ; Elsayed, Hussein G ; Sherisher, Mohamed A ; Elbjeirami, Wafa M ; Alieldin, Nelly</creatorcontrib><description>Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2017.02.008</identifier><identifier>PMID: 28343905</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute leukemia ; Adolescent ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; AYA ; Chemotherapy ; DFCP ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Retrospective Studies ; Saudi Arabia ; Toxicity ; Treatment Outcome ; Young Adult</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2017-05, Vol.17 (5), p.320-325</ispartof><rights>Elsevier Inc.</rights><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-98a954f9cf3d6c7f2be672f1703c962f59d7cd8d878644fa504cd0ff0c35b1963</citedby><cites>FETCH-LOGICAL-c411t-98a954f9cf3d6c7f2be672f1703c962f59d7cd8d878644fa504cd0ff0c35b1963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clml.2017.02.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28343905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alabdulwahab, Amal S</creatorcontrib><creatorcontrib>Elsayed, Hussein G</creatorcontrib><creatorcontrib>Sherisher, Mohamed A</creatorcontrib><creatorcontrib>Elbjeirami, Wafa M</creatorcontrib><creatorcontrib>Alieldin, Nelly</creatorcontrib><title>The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis.</description><subject>Acute leukemia</subject><subject>Adolescent</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>AYA</subject><subject>Chemotherapy</subject><subject>DFCP</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Retrospective Studies</subject><subject>Saudi Arabia</subject><subject>Toxicity</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1uEzEUhUcIREvhBVggL9lksD3_CCGNQguVIoGUIMTK8tjXjVOPnfoHkTfiMXFI6YIFK9vX5xzp3u8WxUuCS4JJ-2ZXCjObkmLSlZiWGPePinNKGrqgbTs8frg3-Kx4FsIO4w5jMjwtzmhf1dWAm_Pi12YL6AO3HF1xP4FHS2eD81GnGX3xLjrhDFLOo5h1Gw88zmAjcgqN0hkIIr8C4lai7y7Zm1xNJhe-6bhFo0gR0Oow77duMjxELdAK0i3Mmr9FI1pre2MAXdv8E1PUzqLLn3vwGqwApC1a8yQ1Gj2fNH9ePFHcBHhxf14UX68uN8tPi9Xnj9fLcbUQNSFxMfR8aGo1CFXJVnSKTtB2VJEOV2JoqWoG2QnZy77r27pWvMG1kFgpLKpmIkNbXRSvT7l77-4ShMhmnbs0hltwKTDS96SuO9wMWUpPUuFdCB4U23s9c39gBLMjIbZjR0LsSIhhyjKhbHp1n5-mGeSD5S-SLHh3EkDu8ocGz4L4MxGpPYjIpNP_z3__j10YbbXg5hYOEHYueZvnxwgL2cDWxx05rghpK9w0La5-A2TGuQA</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Alabdulwahab, Amal S</creator><creator>Elsayed, Hussein G</creator><creator>Sherisher, Mohamed A</creator><creator>Elbjeirami, Wafa M</creator><creator>Alieldin, Nelly</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia</title><author>Alabdulwahab, Amal S ; Elsayed, Hussein G ; Sherisher, Mohamed A ; Elbjeirami, Wafa M ; Alieldin, Nelly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-98a954f9cf3d6c7f2be672f1703c962f59d7cd8d878644fa504cd0ff0c35b1963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute leukemia</topic><topic>Adolescent</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>AYA</topic><topic>Chemotherapy</topic><topic>DFCP</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Retrospective Studies</topic><topic>Saudi Arabia</topic><topic>Toxicity</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alabdulwahab, Amal S</creatorcontrib><creatorcontrib>Elsayed, Hussein G</creatorcontrib><creatorcontrib>Sherisher, Mohamed A</creatorcontrib><creatorcontrib>Elbjeirami, Wafa M</creatorcontrib><creatorcontrib>Alieldin, Nelly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alabdulwahab, Amal S</au><au>Elsayed, Hussein G</au><au>Sherisher, Mohamed A</au><au>Elbjeirami, Wafa M</au><au>Alieldin, Nelly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>17</volume><issue>5</issue><spage>320</spage><epage>325</epage><pages>320-325</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28343905</pmid><doi>10.1016/j.clml.2017.02.008</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2017-05, Vol.17 (5), p.320-325 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1881447059 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acute leukemia Adolescent Antineoplastic Combined Chemotherapy Protocols - therapeutic use AYA Chemotherapy DFCP Female Hematology, Oncology and Palliative Medicine Humans Male Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Retrospective Studies Saudi Arabia Toxicity Treatment Outcome Young Adult |
| title | The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A48%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Dana%20Farber%20Consortium%20Protocol%20for%20the%20Treatment%20of%20Adolescents%20and%20Young%20Adults%20With%20Acute%20Lymphoblastic%20Leukemia:%20A%20Single%20Institution%20Experience%20in%20Saudi%20Arabia&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Alabdulwahab,%20Amal%20S&rft.date=2017-05-01&rft.volume=17&rft.issue=5&rft.spage=320&rft.epage=325&rft.pages=320-325&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2017.02.008&rft_dat=%3Cproquest_cross%3E1881447059%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1881447059&rft_id=info:pmid/28343905&rft_els_id=1_s2_0_S2152265016305560&rfr_iscdi=true |